Summit FY25 GAAP net loss $1.08B, BLA accepted with PDUFA Nov 14, HARMONi-3 interim PFS Q2 2026

Summit Therapeutics Inc.

2025-FY EPS reported -$1.44

GAAP net loss $1,079.6M ($1.44/sh) vs $221.3M ($0.31/sh) FY24; non-GAAP net loss $347.2M ($0.46/sh).
Cash and equivalents $713.4M at Dec 31, 2025, up from $412.3M at Dec 31, 2024.
FDA accepted BLA for ivonescimab+chemo in EGFR-mutated NSCLC; PDUFA goal date Nov 14, 2026.
HARMONi-3 squamous cohort screening complete; interim PFS analysis planned Q2 2026; final PFS H2 2026.
New Phase III ILLUMINE study (GORTEC) in HNSCC to initiate; first patient expected early Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.